Ceftazidime-avibactam susceptibility among KPC-producing enterobacterales in southern Brazil
In: Clinical and Biomedical Research, Jg. 43 (2023-11-01), Heft 3
Online
academicJournal
Zugriff:
Carbapenem-resistant Enterobacterales (CRE) are a subject of global concern as limited therapeutic options are available. New combinations of β-lactams and β-lactamase inhibitors, such as ceftazidime-avibactam (CAZ-AVI), have recently been approved in Brazil for the treatment of CRE infections. Cases of resistance during treatment or even without previous CAZ-AVI use have been published and it is worrisome in scenarios where KPC-producing Gram-negative bacilli are endemic, as in Brazil. We aimed to assess CAZ-AVI susceptibility among a CRE population recovered from hospitalized patients in Southern Brazil from 2015 to 2021. CAZ-AVI minimal inhibitory concentration (MIC) was determined by antibiotic gradient strips. All the 238 evaluated KPC-producing Enterobacterales were susceptible to CAZ-AVI (MIC = 0.25 to 8 µg/mL), with seven isolates presenting borderline MICs (8 µg/mL). Considering the clinical importance of this new antibiotic in Brazil, we emphasize the importance of surveillance studies to eventually detect resistance phenotypes or even increasing CAZ-AVI MICs.
Titel: |
Ceftazidime-avibactam susceptibility among KPC-producing enterobacterales in southern Brazil
|
---|---|
Autor/in / Beteiligte Person: | Natália Kehl Moreira ; Gabriela da Silva Collar ; Priscila Lamb Wink ; Afonso Luís Barth ; Caierão, Juliana |
Link: | |
Zeitschrift: | Clinical and Biomedical Research, Jg. 43 (2023-11-01), Heft 3 |
Veröffentlichung: | Hospital de Clinicas de Porto Alegre ; Universidade Federal do Rio Grande do Sul (UFRGS), 2023 |
Medientyp: | academicJournal |
ISSN: | 2357-9730 (print) |
Schlagwort: |
|
Sonstiges: |
|